Immuron Limited

Immuron Limited

IMRN · Nasdaq

Immuron Limited (IMRN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Immuron Limited in 2026. The next earnings report is expected on August 28, 2026.

Earnings calendar

Next earnings date

28 Aug 2026

In 9 days

EPS estimate

0.00

Revenue estimate

2.7M

Past earnings

25 Feb 2026
EPS actual
-0.20 (-2,584.5%)
estimate -0.01
Revenue actual
3.0M (+3.1%)
estimate 2.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia
Exchange
Nasdaq
CEO
Steven George Lydeamore
Employees
7
IPO date
09 Jun 2017
ISIN
US45254U1016
Website
immuron.com.au

Frequently asked questions

When does Immuron Limited (IMRN) next report earnings?

Immuron Limited (IMRN) is scheduled to report earnings on August 28, 2026.

What was Immuron Limited's most recent earnings date?

Immuron Limited (IMRN) last reported earnings on February 25, 2026.

Where is Immuron Limited stock listed?

Immuron Limited (IMRN) is listed on Nasdaq.